ArticleFrontiers in drug delivery2025
Synergistic mechanotherapy and sonopermeation guided by mathematical modeling for solid tumor treatment.
Article in Frontiers in drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A multiphysics computational model of focused ultrasound-enhanced drug delivery using temperature-sensitive liposomes.Biomechanics and modeling in mechanobiology · 2026Article
- Is there a link between fascia and cancer? From potential mechanisms to future treatment options.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progression of tumors and their response to treatment are significantly influenced by the presence of elevated mechanical solid stress. This solid stress compresses intratumoral blood vessels, leading to reduced blood flow (hypoperfusion) and insufficient oxygen levels (hypoxia), both of which hinder the delivery of oxygen and therapeutic agents. As a result, these conditions promote tumor growth, resistance to treatment, and ultimately undermine the effectiveness of therapies. To address these challenges, strategies like mechanotherapeutics and ultrasound sonopermeation have been developed to enhance blood flow and improve drug delivery to tumors. Mechanotherapy aims to reduce the mechanical stress and stiffness within tumors, helping to decompress vessels and restore normal perfusion. Ultrasound sonopermeation temporarily increases the permeability of blood vessel walls in a non-invasive manner, boosting blood flow and improving the delivery of therapeutic drugs. Here, we developed a mathematical model to explore the combined effects of mechanotherapeutics and sonopermeation on optimizing nano-immunotherapy efficacy. The model integrates complex interactions between key components involved in tumor progression, including tumor cells, immune cells, and vascular elements such as endothelial cells, angiopoietins, and vascular endothelial growth factor. To assess the model's validity, its predictions for key parameters, including tumor volume, functional vascular density, and hypoxia levels, were compared with experimental data, demonstrating a strong correlation, and confirming the accuracy of the mathematical framework. Furthermore, we carried out a parametric analysis to establish critical guidelines aimed at optimizing both the sequence and timing of experimental procedures. Specifically, we investigated the therapeutic outcomes of two treatment scenarios: applying sonopermeation first, followed by nano-immunotherapy, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.